Details of Drug-Drug Interaction
| Drug General Information (ID: DDIY47NRI2) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Erythropoietin | Drug Info | Cyclosporine | Drug Info | |||||
| Drug Type | Hormones | Small molecule | |||||||
| Therapeutic Class | Erythropoiesis Agents | Antiviral Agents | |||||||
| Structure | |||||||||
| Mechanism of Erythropoietin-Cyclosporine Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additive hypertensive effects Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Erythropoietin | Cyclosporine | |||||||
| Mechanism | Hypertensive effects | Hypertensive effects | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Hypertensive effects | ||||||||
| Factor Description | Hypertension is defined as a blood pressure reading above a prescribed limit (130/90 mmHg). Most people with hypertension have no signs or symptoms; others may experience: severe headache, shortness of breath, nosebleeds, severe anxiety, and feeling a tingling sensation in the neck or head. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Caution is advised if cyclosporine is prescribed in combination with ESAs. Blood pressure should be adequately controlled before initiating treatment and monitored periodically during treatment. Patients who develop hypertension that is difficult to control by medications or dietary measures should have their ESA treatment reduced or withheld. In addition, cyclosporine blood levels should be checked regularly, as changes may occur following the addition, withdrawal, or change of dosage of ESA therapy. Dosage adjustments for cyclosporine may be required with increases in hematocrit levels. | ||||||||